Aclidinium bromide

(Tudorza Pressair®)

Aclidinium bromide

Drug updated on 11/9/2023

Dosage FormPowder (inhalation; 400 mcg)
Drug ClassAnticholinergics
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Product Monograph / Prescribing Information

Document TitleYearSource
Tudorza Pressair (aclidinium bromide inhalation powder) Prescribing Information.2021AstraZeneca Pharmaceuticals LP, Wilmington, DE

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines